Skip to main content
Top
Published in: Journal of the International AIDS Society 1/2010

Open Access 01-12-2010 | Research

The importance of clinic attendance in the first six months on antiretroviral treatment: a retrospective analysis at a large public sector HIV clinic in South Africa

Authors: Alana T Brennan, Mhairi Maskew, Ian Sanne, Matthew P Fox

Published in: Journal of the International AIDS Society | Issue 1/2010

Login to get access

Abstract

Background

Adherence to care and treatment are essential for HIV-infected individuals to benefit from antiretroviral therapy (ART). We sought to quantify the effects on treatment outcomes of missing visits soon after initiating ART.

Methods

We analyzed data from HIV-infected patients initiating ART at Themba Lethu Clinic, Johannesburg, South Africa, from April 2004 to August 2008. We used log-binomial regression to evaluate the relative risk of missing visits during the first six months of ART on immunological response and virologic suppression. Cox models were used to evaluate the relationship between missed visits and mortality and loss to follow up over 12 months.

Results

Of 4476 patients, 65% missed no visits, while 26% missed one visit, 7% missed two and 1.6% missed three or more visits during the first six months on treatment. Patients who missed three or more medical or antiretroviral (ARV) visits had a two-fold increased risk of poor CD4 response by six months, while the risk of failing to achieve virologic suppression by six months increased two- to five-fold among patients who missed two and three or more medical or ARV visits. Adjusted Cox models showed that patients who missed two (HR 2.1; 95% CI: 1.0-4.3) and three or more (HR 4.7; 95% CI: 1.4-16.2) medical visits had an increased risk of death, while those who missed two ARV (HR 3.8; 95% CI: 2.5-5.8) or three or more medical (HR 3.0; 95% CI: 1.1-8.1) visits had an increased risk of loss to follow up.

Conclusions

Thirty-five percent of patients missed one or more visits in the first six months on treatment, increasing their risk of poorer outcomes. These patients could be targeted for additional adherence counselling to help improve ART outcomes.
Literature
1.
go back to reference Walensky RP, Wolf LL, Wood R, Fofana MO, Freedberg KA, Martinson NA, Paltiel AD, Anglaret X, Weinstein MC, Losina E: Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis 2008, 197: 1324–1332.CrossRefPubMed Walensky RP, Wolf LL, Wood R, Fofana MO, Freedberg KA, Martinson NA, Paltiel AD, Anglaret X, Weinstein MC, Losina E: Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis 2008, 197: 1324–1332.CrossRefPubMed
2.
go back to reference Lawn SD, Harries AD, Anglaret X, Myer L, Wood R: Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008, 22: 1897–1908.CrossRefPubMed Lawn SD, Harries AD, Anglaret X, Myer L, Wood R: Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008, 22: 1897–1908.CrossRefPubMed
3.
go back to reference Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, Wood R, Laurent C, Sprinz E, Seyler C, Bangsberg DR, Balestre E, Sterne JA, May M, Egger M: Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006, 367: 817–824.CrossRefPubMed Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, Wood R, Laurent C, Sprinz E, Seyler C, Bangsberg DR, Balestre E, Sterne JA, May M, Egger M: Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006, 367: 817–824.CrossRefPubMed
4.
go back to reference Brinkhof M, Dabis F, Myer L, Bangsberg D, Boulle A, Nash D, Schechter M, Laurent C, Keiser O, May M, Sprinz E, Egger M, Anglaret X: Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. WHO Bulletin 2008, 86: 497–576. Brinkhof M, Dabis F, Myer L, Bangsberg D, Boulle A, Nash D, Schechter M, Laurent C, Keiser O, May M, Sprinz E, Egger M, Anglaret X: Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. WHO Bulletin 2008, 86: 497–576.
5.
go back to reference Chêne G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, Dabis F, Lundgren J, D'Arminio Monforte A, de Wolf F, Hogg R, Reiss P, Justice A, Leport C, Staszewski S, Gill J, Fatkenheuer G, Egger ME: Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003, 362: 679–686.CrossRefPubMed Chêne G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, Dabis F, Lundgren J, D'Arminio Monforte A, de Wolf F, Hogg R, Reiss P, Justice A, Leport C, Staszewski S, Gill J, Fatkenheuer G, Egger ME: Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003, 362: 679–686.CrossRefPubMed
6.
go back to reference Carrieri MP, Raffi F, Lewden C, Sobel A, Michelet C, Cailleton V, Chêne G, Leport C, Moatti JP, Spire B: Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virologic response: a 3-year follow-up study. Antivir Ther 2003, 8: 585–594.PubMed Carrieri MP, Raffi F, Lewden C, Sobel A, Michelet C, Cailleton V, Chêne G, Leport C, Moatti JP, Spire B: Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virologic response: a 3-year follow-up study. Antivir Ther 2003, 8: 585–594.PubMed
7.
go back to reference Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, Karungi G, Szumilin E, Balandine S, Fedida G, Carrieri MP, Spire B, Ford N, Tassie JM, Guerin PJ, Brasher C: Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 2006, 367: 1335–1342.CrossRefPubMed Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, Karungi G, Szumilin E, Balandine S, Fedida G, Carrieri MP, Spire B, Ford N, Tassie JM, Guerin PJ, Brasher C: Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 2006, 367: 1335–1342.CrossRefPubMed
8.
go back to reference Myer L, el Sadr W: Expanding access to antiretroviral therapy through the public sector--the challenge of retaining patients in long-term primary care. S Afr Med J 2004, 94: 273–274.PubMed Myer L, el Sadr W: Expanding access to antiretroviral therapy through the public sector--the challenge of retaining patients in long-term primary care. S Afr Med J 2004, 94: 273–274.PubMed
9.
go back to reference Yu JK, Chen SC, Wang KY, Chang CS, Makombe SD, Schouten EJ, Harries AD: True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi. Bull World Health Organ 2007, 85: 550–554.CrossRefPubMed Yu JK, Chen SC, Wang KY, Chang CS, Makombe SD, Schouten EJ, Harries AD: True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi. Bull World Health Organ 2007, 85: 550–554.CrossRefPubMed
10.
go back to reference Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, Wood R: Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis 2006, 43: 770–776.CrossRefPubMed Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, Wood R: Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis 2006, 43: 770–776.CrossRefPubMed
11.
go back to reference Nacheqa JB, Mills EJ, Schechter M: Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities. Curr Opin HIV/AIDS 2010, 5 (1) : 70–77.CrossRef Nacheqa JB, Mills EJ, Schechter M: Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities. Curr Opin HIV/AIDS 2010, 5 (1) : 70–77.CrossRef
12.
go back to reference Orrell C: Antiretroviral adherence in a resource-poor setting. Curr HIV/AIDS Rep 2005, 2 (4) : 171–176.CrossRefPubMed Orrell C: Antiretroviral adherence in a resource-poor setting. Curr HIV/AIDS Rep 2005, 2 (4) : 171–176.CrossRefPubMed
13.
go back to reference Garnder EM, Burman WJ, Maravi ME, Davidson AJ: Antiretroviral medication adherence and class-specific resistance in a large prospective clinical trial. AIDS 2010, 24 (3) : 395–403.CrossRef Garnder EM, Burman WJ, Maravi ME, Davidson AJ: Antiretroviral medication adherence and class-specific resistance in a large prospective clinical trial. AIDS 2010, 24 (3) : 395–403.CrossRef
14.
go back to reference Lucas GM, Chaisson RE, Moore RD: Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999, 131: 81–87.PubMed Lucas GM, Chaisson RE, Moore RD: Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999, 131: 81–87.PubMed
15.
go back to reference Rastegar DA, Fingerhood MI, Jasinski DR: Highly active antiretroviral therapy outcomes in a primary care clinic. AIDS Care 2003, 15: 231–237.CrossRefPubMed Rastegar DA, Fingerhood MI, Jasinski DR: Highly active antiretroviral therapy outcomes in a primary care clinic. AIDS Care 2003, 15: 231–237.CrossRefPubMed
16.
go back to reference Mugavero MJ, Lin HY, Willig JH, Westfall AO, Ulett KB, Routman JS, Abroms S, Raper JL, Saag MS, Allison JJ: Missed Visit and Mortality among Patients Establishing Initial Outpatient HIV Treatment. Clin Infect Dis 2009, 48 (2) : 248–256.CrossRefPubMed Mugavero MJ, Lin HY, Willig JH, Westfall AO, Ulett KB, Routman JS, Abroms S, Raper JL, Saag MS, Allison JJ: Missed Visit and Mortality among Patients Establishing Initial Outpatient HIV Treatment. Clin Infect Dis 2009, 48 (2) : 248–256.CrossRefPubMed
17.
go back to reference Giordano TP, Gifford AL, White AC Jr, Suarez-Almazor ME, Rabeneck L, Hartman C, Backus LI, Mole LA, Morgan RO: Retention in care: a challenge to survival with HIV infection. Clin Infect Dis 2007, 44: 1493–1499.CrossRefPubMed Giordano TP, Gifford AL, White AC Jr, Suarez-Almazor ME, Rabeneck L, Hartman C, Backus LI, Mole LA, Morgan RO: Retention in care: a challenge to survival with HIV infection. Clin Infect Dis 2007, 44: 1493–1499.CrossRefPubMed
18.
go back to reference Berg MB, Safren SA, Mimiaga MJ, Grasso C, Boswell S, Mayer KH: Non-adherence to medical appointments is associated with increased plasma HIV RNA and decreased CD4 cell counts in a community based HIV primary care clinic. AIDS Care 2005, 17 (7) : 902–907.PubMed Berg MB, Safren SA, Mimiaga MJ, Grasso C, Boswell S, Mayer KH: Non-adherence to medical appointments is associated with increased plasma HIV RNA and decreased CD4 cell counts in a community based HIV primary care clinic. AIDS Care 2005, 17 (7) : 902–907.PubMed
19.
go back to reference Sethi A, Celentano D, Gange S, Moore R, Gallant J: Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 2003, 37 (8) : 1112–1118.CrossRefPubMed Sethi A, Celentano D, Gange S, Moore R, Gallant J: Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 2003, 37 (8) : 1112–1118.CrossRefPubMed
20.
go back to reference Valdez H, Lederman MM, Woolley I, Walker CJ, Vernon LT, Hise A, Gripshover BM: Human immunodeficiency virus 1 protease inhibitors in clinical practice: predictors of virological outcome. Arch Intern Med 1999, 159 (15) : 1771–1776.CrossRefPubMed Valdez H, Lederman MM, Woolley I, Walker CJ, Vernon LT, Hise A, Gripshover BM: Human immunodeficiency virus 1 protease inhibitors in clinical practice: predictors of virological outcome. Arch Intern Med 1999, 159 (15) : 1771–1776.CrossRefPubMed
21.
go back to reference Gifford AL, Groessl EJ: Chronic Disease Self-Management and adherence to HIV Medications. JAIDS 2002, 31: S163-S166.PubMed Gifford AL, Groessl EJ: Chronic Disease Self-Management and adherence to HIV Medications. JAIDS 2002, 31: S163-S166.PubMed
22.
go back to reference Nash D, Katyal M, Brinkhof MW, Keiser O, May M, Hughes R, Dabis F, Wood R, Sprinz E, Schechter M, Egger M: Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS 2008, 22 (17) : 2291–2302.CrossRefPubMed Nash D, Katyal M, Brinkhof MW, Keiser O, May M, Hughes R, Dabis F, Wood R, Sprinz E, Schechter M, Egger M: Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS 2008, 22 (17) : 2291–2302.CrossRefPubMed
23.
go back to reference National Department of Health, Republic of South Africa: National Antiretroviral Treatment Guidelines. Jacana Publishers; 2004. National Department of Health, Republic of South Africa: National Antiretroviral Treatment Guidelines. Jacana Publishers; 2004.
24.
go back to reference Fairall LR, Bachmann MO, Louwagie GM, van Vuuren C, Chikobvu P, Steyn D, Staniland GH, Timmerman V, Msimanga M, Seebregts CJ, Boulle A, Nhiwatiwa R, Bateman ED, Zwarenstein MF, Chapman RD: Effectiveness of antiretroviral treatment in a South African program: a cohort study. Arch Intern Med 2008, 168: 86–93.CrossRefPubMed Fairall LR, Bachmann MO, Louwagie GM, van Vuuren C, Chikobvu P, Steyn D, Staniland GH, Timmerman V, Msimanga M, Seebregts CJ, Boulle A, Nhiwatiwa R, Bateman ED, Zwarenstein MF, Chapman RD: Effectiveness of antiretroviral treatment in a South African program: a cohort study. Arch Intern Med 2008, 168: 86–93.CrossRefPubMed
25.
go back to reference Fox MP, Brennan A, Maskew M, MacPhail P, Sanne I: Using vital registration data to update mortality among patients lost to follow-up from ART programmes: evidence from the Themba Lethu Clinic, South Africa. Trop Med Int Health 2010, 15 (4) : 405–413.PubMed Fox MP, Brennan A, Maskew M, MacPhail P, Sanne I: Using vital registration data to update mortality among patients lost to follow-up from ART programmes: evidence from the Themba Lethu Clinic, South Africa. Trop Med Int Health 2010, 15 (4) : 405–413.PubMed
26.
go back to reference Boulle A, Van Cutsem G, Hilderbrand K, Cragg C, Abrahams M, Mathee S, Ford N, Knight L, Osler M, Myers J, Goemaere E, Coetzee D, Maartens G: Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS 2010, 24 (4) : 563–572.CrossRefPubMed Boulle A, Van Cutsem G, Hilderbrand K, Cragg C, Abrahams M, Mathee S, Ford N, Knight L, Osler M, Myers J, Goemaere E, Coetzee D, Maartens G: Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS 2010, 24 (4) : 563–572.CrossRefPubMed
27.
go back to reference World Health Organization: More than five million people receiving HIV treatment: WHO advises earlier treatment among people with HIV approach. In XVIII International AIDS Conference 2010. Vienna, Austria; 2010. World Health Organization: More than five million people receiving HIV treatment: WHO advises earlier treatment among people with HIV approach. In XVIII International AIDS Conference 2010. Vienna, Austria; 2010.
28.
go back to reference Catz SL, McClure JB, Jones GN, Brantley PJ: Predictors of outpatient medical appointment attendance among persons with HIV. AIDS Care 1999, 11 (3) : 361–373.CrossRefPubMed Catz SL, McClure JB, Jones GN, Brantley PJ: Predictors of outpatient medical appointment attendance among persons with HIV. AIDS Care 1999, 11 (3) : 361–373.CrossRefPubMed
29.
go back to reference Israelski D, Gore-Felton C, Power R, Wood MJ, Koopman C: Sociodemographic characteristics associated with medical appointment adherence among HIV-seropositive patients seeking treatment in a county outpatient facility. Prev Med 2001, 33 (5) : 470–475.CrossRefPubMed Israelski D, Gore-Felton C, Power R, Wood MJ, Koopman C: Sociodemographic characteristics associated with medical appointment adherence among HIV-seropositive patients seeking treatment in a county outpatient facility. Prev Med 2001, 33 (5) : 470–475.CrossRefPubMed
30.
go back to reference McClure JB, Catz SL, Brantley PJ: Early appointment adherence among persons living with HIV. AIDS Behavior 1999, 3 (2) : 157–165.CrossRef McClure JB, Catz SL, Brantley PJ: Early appointment adherence among persons living with HIV. AIDS Behavior 1999, 3 (2) : 157–165.CrossRef
31.
go back to reference Arici C, Ripamonti D, Maggiolo F, Rizzi M, Finazzi MG, Pezzotti P, Suter F: Factors associated with the failure of HIV-positive persons to return for scheduled medical visits. HIV Clin Trials 2002, 3 (1) : 52–57.CrossRefPubMed Arici C, Ripamonti D, Maggiolo F, Rizzi M, Finazzi MG, Pezzotti P, Suter F: Factors associated with the failure of HIV-positive persons to return for scheduled medical visits. HIV Clin Trials 2002, 3 (1) : 52–57.CrossRefPubMed
32.
go back to reference Nemes MI, Carvalho HB, Souza MF: Antiretroviral therapy adherence in Brazil. AIDS 2004, 18 (Suppl 3) : S15-S20.CrossRefPubMed Nemes MI, Carvalho HB, Souza MF: Antiretroviral therapy adherence in Brazil. AIDS 2004, 18 (Suppl 3) : S15-S20.CrossRefPubMed
33.
go back to reference Silverberg MJ, Leyden W, Horberg MA, DeLorenze GN, Klein D, Quesenberry CP: Older Age and the Response to and Tolerability of Antiretroviral Therapy. Arch Intern Med 2007, 167: 684–691.CrossRefPubMed Silverberg MJ, Leyden W, Horberg MA, DeLorenze GN, Klein D, Quesenberry CP: Older Age and the Response to and Tolerability of Antiretroviral Therapy. Arch Intern Med 2007, 167: 684–691.CrossRefPubMed
34.
go back to reference The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group: Response to combination antiretroviral therapy: variation by age. AIDS 2008, 22: 1463–1473.CrossRef The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group: Response to combination antiretroviral therapy: variation by age. AIDS 2008, 22: 1463–1473.CrossRef
35.
go back to reference Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, Battegay M, Vernazza P, Bernasconi E, Opravil M, Kaufmann D, Sudre P, Francioli P, Telenti A: AIDS-Related Opportunistic Illnesses Occurring After Initiation of Potent Antiretroviral Therapy. JAMA 1999, 282 (23) : 2220–2226.CrossRefPubMed Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, Battegay M, Vernazza P, Bernasconi E, Opravil M, Kaufmann D, Sudre P, Francioli P, Telenti A: AIDS-Related Opportunistic Illnesses Occurring After Initiation of Potent Antiretroviral Therapy. JAMA 1999, 282 (23) : 2220–2226.CrossRefPubMed
36.
go back to reference Lawn SD, Little F, Bekker L, Kaplan R, Campbel E, Orrell E, Wood R: Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS 2009, 23 (3) : 335–342.CrossRefPubMed Lawn SD, Little F, Bekker L, Kaplan R, Campbel E, Orrell E, Wood R: Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS 2009, 23 (3) : 335–342.CrossRefPubMed
37.
go back to reference Chi BH, Giganti M, Mulenga PL, Limbada M, Reid SE, Mutale W, Stringer JS: CD4+ response and subsequent risk of death among patients on antiretroviral therapy in Lusaka, Zambia. JAIDS 2009, 52 (1) : 125–131.CrossRefPubMed Chi BH, Giganti M, Mulenga PL, Limbada M, Reid SE, Mutale W, Stringer JS: CD4+ response and subsequent risk of death among patients on antiretroviral therapy in Lusaka, Zambia. JAIDS 2009, 52 (1) : 125–131.CrossRefPubMed
38.
go back to reference Poole WK, Perritt R, Shah KB, Lou Y, Turner J, Kvale P, Hopewell PC, Glassroth J, Rosen M, Reichman L, Wallace J: A characterisation of patient drop outs in a cohort of HIV positive homosexual/bisexual men and intravenous drug users. J Epidemiol Community Health 2001, 55 (1) : 66–67.CrossRefPubMed Poole WK, Perritt R, Shah KB, Lou Y, Turner J, Kvale P, Hopewell PC, Glassroth J, Rosen M, Reichman L, Wallace J: A characterisation of patient drop outs in a cohort of HIV positive homosexual/bisexual men and intravenous drug users. J Epidemiol Community Health 2001, 55 (1) : 66–67.CrossRefPubMed
39.
go back to reference Rumptz MH, Tobias C, Rajabiun S, Bradford JB, Cabral HJ, Young R, Cunningham WE: Factors associated with engaging socially marginalized HIV-positive persons in primary care. AIDS Patient Care STDS 2007, 21 (1) : 30–39.CrossRef Rumptz MH, Tobias C, Rajabiun S, Bradford JB, Cabral HJ, Young R, Cunningham WE: Factors associated with engaging socially marginalized HIV-positive persons in primary care. AIDS Patient Care STDS 2007, 21 (1) : 30–39.CrossRef
40.
go back to reference Fox MP, Mazimba A, Seidenberg P, Crooks D, Sikateyo B, Rosen S: Barriers to initiation of antiretroviral treatment in rural and urban areas of Zambia: a cross-sectional study of cost, stigma, and perceptions about ART. Journal of the International AIDS Society 2010, 13: 8.CrossRefPubMed Fox MP, Mazimba A, Seidenberg P, Crooks D, Sikateyo B, Rosen S: Barriers to initiation of antiretroviral treatment in rural and urban areas of Zambia: a cross-sectional study of cost, stigma, and perceptions about ART. Journal of the International AIDS Society 2010, 13: 8.CrossRefPubMed
Metadata
Title
The importance of clinic attendance in the first six months on antiretroviral treatment: a retrospective analysis at a large public sector HIV clinic in South Africa
Authors
Alana T Brennan
Mhairi Maskew
Ian Sanne
Matthew P Fox
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Journal of the International AIDS Society / Issue 1/2010
Electronic ISSN: 1758-2652
DOI
https://doi.org/10.1186/1758-2652-13-49

Other articles of this Issue 1/2010

Journal of the International AIDS Society 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.